[Results of rubella prevention in Austria (1988 status)].
The aim of any rubella eradication programme is the prevention of rubella embryopathy. In Austria, every girl aged 13 years is vaccinated without prior antibody testing. In addition, all pregnant women are tested for antibodies and vaccinated post partum, if necessary. As in other European countries, this policy has not (yet) led to the elimination of rubella embryopathies. In 1987 and 1988, 3 embryopathies as well as 16 and 17, respectively, rubella infections in pregnant women were diagnosed. In order to monitor the effectiveness of the vaccination in 13 years old girls, we tested 325 sera from student nurses (mean age 15.6 years) as well as 895 sera from pregnant women (mean age 23.1 years). In the 1st group, only 2.2% had a titer of less than or equal to 16 in hemagglutination inhibition test and therefore were not unequivocally protected. In the pregnant women, this ratio was 6.1%. We therefore draw the conclusion that in some cases the protection afforded by the vaccination begins to decrease after 10 years. At the same time, we also tested the sera of 4186 pregnant women who claimed they never had been vaccinated. Their mean age was higher (26 years) and 11.1% were not unequivocally protected. In addition, we tested 28 women who had been vaccinated 3 to 6 months previously due to negative serology. Of these, 6 (21.4%) did not produce antibodies with a titer of at least 32. Many European countries had the same experience and therefore began vaccinations of all children in the 2nd year, using the trivalent vaccine (mumps, measles, rubella) instead of the bivalent one (without rubella).(ABSTRACT TRUNCATED AT 250 WORDS)
Institut für Virologie, Universität Wien.
H
H
Hofmann
C
C
Kunz
D000293:Adolescent; D000328:Adult; D000914:Antibodies, Viral / Q000032:analysis*; D001317:Austria; D005260:Female; D006801:Humans; D007075:Immunoglobulin M / Q000032:analysis; D007231:Infant, Newborn; D008403:Mass Screening; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000517:prevention & control*; D012409:Rubella / Q000517:prevention & control*; D012410:Rubella Syndrome, Congenital / Q000517:prevention & control*; D012411:Rubella Vaccine / Q000008:administration & dosage*; D012412:Rubella virus / Q000276:immunology*
D000914:Antibodies, Viral; D007075:Immunoglobulin M; D012411:Rubella Vaccine; C040901:rubella antibodies
Ergebnisse der Rötelnvorsorge in Osterreich (Stand 1988).